<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disseminated intravascular coagulation (DIC) during pregnancy: Clinical findings, etiology, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disseminated intravascular coagulation (DIC) during pregnancy: Clinical findings, etiology, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Disseminated intravascular coagulation (DIC) during pregnancy: Clinical findings, etiology, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael A Belfort, MBBCH, MD, PhD, D.A. (SA), FRCSC, FRCOG, FACOG</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David L Hepner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynne Uhl, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Disseminated intravascular coagulation (DIC) is a pathologic disruption of the finely balanced process of hemostasis. The systemic activation of coagulation is characterized by generation and deposition of fibrin and formation of microvascular thrombi (thrombosis) in the small blood vessels throughout the body, eventually leading to multiple organ dysfunction. Widespread clotting depletes platelets and clotting factors that are needed to control bleeding, which often leads to excessive bleeding. Activation of plasmin-mediated fibrinolysis by intravascular fibrin is another component of the process.</p><p>Identification and treatment of the underlying cause are critical to resolution of the hemostatic abnormalities. Any patient with DIC presents a major management challenge, and this challenge is further complicated when the patient is carrying a fetus at a stage of fetal maturity when there is a reasonable chance of extrauterine survival. For example, delaying delivery to transfuse a pregnant patient with DIC who is bleeding heavily may not be in the best interest of a fetus with a category III heart rate tracing, whereas performing an emergency cesarean birth on this patient may not be in their best interest. Even in the setting of fetal demise, labor and vaginal birth of a pregnant patient with DIC carries the potential for catastrophic hemorrhage.</p><p>This topic will review DIC related to pregnancy, focusing on clinical findings, etiology, and diagnosis. The management and prognosis of pregnant patients with DIC or another severe coagulopathy are discussed separately. (See  <a class="medical medical_review" href="/d/html/130462.html" rel="external">"Disseminated intravascular coagulation (DIC) during pregnancy: Management and prognosis"</a>.)</p><p>Broader discussions of the pathogenesis, clinical manifestations, diagnosis, and treatment of DIC can be found elsewhere (see  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>). Other causes of pregnancy-associated thrombocytopenia and obstetric hemorrhage are also presented elsewhere. (See  <a class="medical medical_review" href="/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/6799.html" rel="external">"Evaluation and differential diagnosis of vaginal bleeding before 20 weeks of gestation"</a>.)</p><p class="headingAnchor" id="H593599758"><span class="h1">PREVALENCE</span></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy-associated DIC accounts for approximately 1 to 5 percent of all cases of DIC in resource-abundant countries; this proportion appears to be higher in resource-limited countries [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of pregnancy-associated DIC ranges from 0.03 to 0.35 percent of delivery hospitalizations in population-based studies [<a href="#rid2">2-4</a>]. A study from the United States reported a prevalence of 12.5 per 10,000 delivery hospitalizations (0.13 percent) [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the overall prevalence of pregnancy-associated DIC is low, patients with specific pregnancy complications, such as placental abruption or amniotic fluid embolism, can be at very high risk (eg, prevalence &gt;20 percent) [<a href="#rid5">5-7</a>].</p><p></p><p class="headingAnchor" id="H817239223"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathogenesis and consequences of DIC are shown in the figure  (<a class="graphic graphic_figure graphicRef98047" href="/d/graphic/98047.html" rel="external">figure 1</a>) and discussed in detail separately. In pregnancy, impaired uterine contractility is an additional important clinical consequence [<a href="#rid8">8-10</a>]. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Pathogenesis'</a>.)</p><p>DIC is a secondary manifestation of an underlying condition that has led to uncontrolled activation of clot formation and breakdown. In pregnant patients, the underlying condition is often placental abruption, amniotic fluid embolism, or fetal demise with necrosis. These conditions result in generation of, or exposure to, tissue factor (TF) [<a href="#rid11">11-13</a>]. TF interacts with circulating factor VIIa to rapidly initiate the clotting cascade via the extrinsic pathway  (<a class="graphic graphic_figure graphicRef90873" href="/d/graphic/90873.html" rel="external">figure 2</a>). </p><p class="headingAnchor" id="H1949821"><span class="h1">CAUSES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy-related</strong> – The type and frequency of pregnancy-related conditions that triggered DIC in a review of 49 cases from a tertiary maternity hospital included [<a href="#rid3">3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Placental abruption</strong> – 37 percent (See  <a class="medical medical_review" href="/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"</a> and  <a class="medical medical_review" href="/d/html/6803.html" rel="external">"Acute placental abruption: Management and long-term prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Postpartum hemorrhage</strong> – 29 percent (See  <a class="medical medical_review" href="/d/html/6710.html" rel="external">"Overview of postpartum hemorrhage"</a>.)</p><p></p><p class="bulletIndent2">There is some debate about the relationship between severe postpartum hemorrhage (PPH) and DIC. There is evidence that severe tissue hypoxia in the setting of shock may result in release of tissue factor (TF) from damaged cells and supraphysiologic activation of coagulation, leading to DIC [<a href="#rid14">14,15</a>]. The counterargument is that coagulopathy in the setting of PPH is simply due to depletion of clotting factors and platelets by blood loss, which results in dilutional coagulopathy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preeclampsia/eclampsia/HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome</strong> – 14 percent. These cases were likely complicated by coexistent abruption or liver failure, as most preeclampsia is associated with thrombocytopenia without changes in prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a> and  <a class="medical medical_review" href="/d/html/1662.html" rel="external">"Eclampsia"</a> and  <a class="medical medical_review" href="/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute fatty liver</strong> – 8 percent (See  <a class="medical medical_review" href="/d/html/3619.html" rel="external">"Acute fatty liver of pregnancy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Amniotic fluid embolism</strong> – 6 percent (See  <a class="medical medical_review" href="/d/html/1591.html" rel="external">"Amniotic fluid embolism"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy-related sepsis</strong> – 6 percent. Examples include septic abortion, severe chorioamnionitis, and postpartum endometritis. (See  <a class="medical medical_review" href="/d/html/14192.html" rel="external">"Unsafe abortion", section on 'Morbidity and mortality'</a> and  <a class="medical medical_review" href="/d/html/5442.html" rel="external">"Pregnancy loss (miscarriage): Clinical presentations, diagnosis, and initial evaluation", section on 'Septic abortion'</a> and  <a class="medical medical_review" href="/d/html/6762.html" rel="external">"Clinical chorioamnionitis"</a> and  <a class="medical medical_review" href="/d/html/5488.html" rel="external">"Postpartum endometritis"</a>.)</p><p></p><p class="bulletIndent1">There were no cases of prolonged retention of a dead fetus because these cases are generally identified early and delivered without significant delay in contemporary obstetric practice [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/6740.html" rel="external">"Stillbirth: Maternal care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpregnancy-related</strong> – DIC may also be caused by conditions that may occur in the nonpregnant population. The most common events that initiate DIC in the general population are sepsis, trauma, and cancer  (<a class="graphic graphic_table graphicRef58104" href="/d/graphic/58104.html" rel="external">table 1</a>). The possibility of these nonobstetric causes of DIC should be considered in pregnant patients with DIC, especially when an obvious pregnancy-associated cause is absent [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Causes of DIC'</a>.)</p><p></p><p class="headingAnchor" id="H1950009"><span class="h1">CLINICAL FINDINGS</span></p><p class="headingAnchor" id="H194036959"><span class="h2">Presentation</span><span class="headingEndMark"> — </span>DIC typically occurs in the setting of one of the pregnancy complications described above (see <a class="local">'Causes'</a> above). It may present in either of two ways, depending on the underlying etiology, intensity of coagulation activation, and the deficiency of natural anticoagulation mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overt DIC</strong> – Overt fulminant DIC is the more common scenario in pregnancy. Coagulation and fibrinolysis are both increased, and both overt bleeding and thrombosis are present. Patients may present with severe vaginal bleeding and/or diffuse oozing from skin (eg, at intravenous sites) or mucosa (eg, from a bladder catheter). Signs of shock (eg, tachycardia, hypotension, weak peripheral pulses, altered mental status, cool extremities, narrow pulse pressure [&lt;25 mmHg]) and/or organ dysfunction (eg, acute renal failure, hepatic dysfunction, acute lung injury, neurologic dysfunction) may be present. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Importantly, patients with abruption may not have vaginal bleeding early in the course of the disorder if most of the blood is initially retained in utero behind the placenta (called "concealed abruption"). Patients with intraabdominal bleeding also do not present with vaginal bleeding. Severe intraabdominal bleeding is uncommon but can occur in the setting of hepatic rupture related to preeclampsia, eclampsia, or HELLP syndrome-associated hepatic disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Latent and compensated activation of coagulation</strong> – In this situation, there is subtle hemostatic dysfunction and increased thrombotic risk without<strong> </strong>obvious clinical symptoms or signs. It is characterized by imbalance between activation and inhibition of the coagulation system and can be rapidly normalized by removing the procoagulant stimulus and enhancing the inhibitory mechanisms. This state may become a chronic condition, which is rare in pregnancy, or it may progress to overt DIC. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Acute versus chronic DIC'</a>.)</p><p></p><p class="headingAnchor" id="H194036965"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>No single laboratory test is sensitive and specific for DIC. Laboratory findings generally include abnormal coagulation studies and thrombocytopenia. These findings need to be interpreted within the context of normal reference values in pregnancy  (<a class="graphic graphic_table graphicRef89013" href="/d/graphic/89013.html" rel="external">table 2</a>), which are sometimes different from values in nonpregnant patients. Normal pregnancy is a hypercoagulable state. Changes include marked increases in most coagulation factors, increased platelet reactivity, decreased endogenous anticoagulation, and decreased fibrinolysis. This shift in the hemostatic and fibrinolytic systems serves to prevent excessive bleeding during placental separation. (See  <a class="medical medical_review" href="/d/html/417.html" rel="external">"Normal reference ranges for laboratory values in pregnancy"</a>.)</p><p>Major findings in DIC include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – The platelet count is typically mildly to moderately reduced; platelet counts below 20,000/microL are uncommon [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">In normal pregnancy, the mean platelet count is slightly lower than in nonpregnant patients (called gestational thrombocytopenia) but usually remains within the normal range. Because platelet counts may be within the normal range in the early stages of DIC, the trend in platelet count should be monitored when DIC is suspected. In a clinical scenario that includes DIC in the differential diagnosis, a falling platelet count may be a sign of developing DIC even if the absolute count is in the normal range.</p><p></p><p class="bulletIndent1">Thrombocytopenia in pregnancy is not specific for DIC; it is observed in several pregnancy-related disorders. (See  <a class="medical medical_review" href="/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolongation of the activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin time (TT)</strong> – The aPTT and PT measure the time taken, in vitro, for blood to form fibrin. The PT/international normalized ratio (INR) evaluates the extrinsic pathway, and the aPTT measures the time taken to form fibrin via the intrinsic pathway.</p><p></p><p class="bulletIndent1">Both PT/INR and aPTT are prolonged. In a normal gestation, the aPTT and PT/INR may be slightly shorter than that in nonpregnant patients due to normal changes in coagulation factors. This can cause a delay in the recognition of ongoing coagulopathy since prolongation/increase in the aPTT and PT/INR may not become obvious until the causative pathology is well advanced [<a href="#rid21">21</a>]. Thus, it is essential to note any prolongation/increase of the aPTT and PT/INR, even if the starting point is within the normal range and the current aPTT and PT/INR are still within that normal range. A widening differential between baseline and repeat tests in either the aPTT or the PT/INR may indicate clinical worsening [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/429.html" rel="external">"Maternal adaptations to pregnancy: Hematologic changes", section on 'Coagulation and fibrinolysis'</a>.)</p><p></p><p class="bulletIndent1">The TT is another coagulation test that measures the final step in the coagulation cascade (conversion of fibrinogen to fibrin). The TT is not routinely measured in pregnancy or DIC, but if measured, it tends to follow the same pattern as the aPTT and PT/INR (ie, it is shorter than normal in normal pregnancy and prolonged in DIC) [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypofibrinogenemia</strong> – Fibrinogen levels fall in DIC. In a normal pregnancy, the fibrinogen level is &gt;300 mg/dL in the third trimester, a level that is substantially higher than in nonpregnant individuals, since fibrinogen is an acute phase reactant [<a href="#rid24">24</a>]. Reduction in the fibrinogen level from the patient's baseline is concerning even if the absolute level remains in the normal range, as the fall in fibrinogen in DIC can be a relatively late finding [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">In a study of patients with persistent uterine atony, a fibrinogen level &lt;200 mg/dL had a positive predictive value of 100 percent for progression to severe postpartum hemorrhage, whereas a level &gt;400 mg/dL had a negative predictive value of 79 percent [<a href="#rid26">26</a>]. The greatest concern for bleeding generally occurs when the fibrinogen level is &lt;100 mg/dL; this is also the typical level below which the aPTT and PT/INR become prolonged/increased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased D-dimer</strong> – D-dimer is increased in DIC. In a normal pregnancy, D-dimer is higher than in nonpregnant individuals [<a href="#rid27">27,28</a>]. In one study of 760 healthy patients with singleton pregnancies, the D-dimer median value was 316 ng/mL at 24 weeks, gradually increasing to 668 ng/mL at 40 weeks; the 95<sup>th</sup> percentiles at 24 and 40 weeks were 704 ng/mL and 1538 ng/mL, respectively [<a href="#rid27">27</a>]. D-dimer is further increased in DIC, but because of the higher baseline values in pregnancy, a positive D-dimer test and the absolute D-dimer value are difficult to interpret.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variable white blood cell (WBC) count</strong> – The WBC count is increased in pregnancy, particularly during labor. In DIC, it may be normal, increased, or decreased (eg, due to sepsis). (See  <a class="medical medical_review" href="/d/html/429.html" rel="external">"Maternal adaptations to pregnancy: Hematologic changes", section on 'White blood cells'</a>.)</p><p></p><p class="headingAnchor" id="H147348577"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Evaluation for DIC may need to occur concurrently with initial management before the diagnosis is completely established, especially if there is ongoing hemorrhage, shock, or an abnormal fetal heart rate pattern. (See  <a class="medical medical_review" href="/d/html/130462.html" rel="external">"Disseminated intravascular coagulation (DIC) during pregnancy: Management and prognosis", section on 'Initial preparation and assessment of all patients'</a>.) </p><p>Many pregnancy-associated causes of DIC are obvious from the history and physical examination. Because the absence of external bleeding does not exclude overt DIC, any pregnant patient with features consistent with DIC should be evaluated for intraabdominal (intraperitoneal and retroperitoneal) hemorrhage and large vaginal or vulvar hematomas. Pregnant patients who have been involved in trauma can lose large amounts of blood into the soft tissues (eg, a fractured femur can bleed into the thigh).</p><p>Laboratory testing includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count (CBC) with differential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coagulation studies including prothrombin time (PT) and international normalized ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen level, and D-dimer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver biochemical and function tests (alanine aminotransferase, aspartate aminotransferase, albumin, bilirubin) – Normal results in the setting of coagulopathy suggests DIC, whereas very abnormal results suggest that at least part of the pathology leading to the coagulopathy may be liver failure and failure to produce adequate coagulation factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thromboelastography (TEG)/Rotational thromboelastometry (ROTEM). This information provides a global assessment of hemostasis in whole blood that includes contributions of platelets, fibrinogen, fibrinolysis, and coagulation factors. TEG/ROTEM can be particularly useful in diagnosing dilutional coagulopathy [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management", section on 'Viscoelastic testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood urea nitrogen and creatinine, as acute kidney injury occurs in 25 to 40 percent of patients with acute DIC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood and urine cultures in patients with suspected sepsis. In cases where intrauterine infection is suspected, aspiration of amniotic fluid for culture is appropriate.</p><p></p><p>Prior to the return of the first set of laboratory results, a crude clotting time may be performed using any of a variety of methods [<a href="#rid30">30</a>]. One method is to determine the clotting time of 5 mL of blood in a red top tube (ie, no additives) at room temperature; if the blood in the tube clots within 8 to 10 minutes and the clot remains intact, the patient likely has adequate fibrinogen stores. If the blood in the tube does not clot or an initial clot dissolves, it is likely that the patient is markedly deficient in key clotting factors. However, such tests are highly subjective, insensitive, imprecise, and not validated in pregnancy.</p><p>Although serial coagulation testing is rarely necessary to diagnose DIC in the obstetric setting (where DIC is typically fulminant), serial laboratory assessments over a few hours in less fulminant cases may show progressively prolonged coagulation times, decreasing platelet counts, increasing values for D-dimer, and falling fibrinogen levels. In challenging cases, this pattern can help distinguish mild DIC from normal pregnancy-related changes in these laboratory values. Serial CBCs, fibrinogen levels, and coagulation tests are important for guiding management (eg, coagulation factor replacement). (See  <a class="medical medical_review" href="/d/html/130462.html" rel="external">"Disseminated intravascular coagulation (DIC) during pregnancy: Management and prognosis", section on 'Measure blood loss'</a>.)</p><p class="headingAnchor" id="H147348504"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>We make the diagnosis of acute DIC in a pregnant patient when the clinical setting is appropriate (eg, placental abruption, amniotic fluid embolism, acute fatty liver, sepsis) and there is laboratory evidence of thrombocytopenia, coagulation factor consumption (eg, prolonged prothrombin time and activated partial thromboplastin time; low fibrinogen), and fibrinolysis (eg, increasing D-dimer), as long as another etiology for these findings does not become apparent. No single laboratory test is highly sensitive or specific for the diagnosis.</p><p>Early involvement of a hematology specialist is advised when the cause is not thought to be one of the more common obstetric causes described above. (See <a class="local">'Causes'</a> above.) Specific steps to evaluate the likelihood of DIC and eliminate other possibly life-threatening causes of the findings, such as thrombotic thrombocytopenic purpura, can then be taken. (See <a class="local">'Differential diagnosis'</a> below.) </p><p class="headingAnchor" id="H2307188298"><span class="h2">Scoring systems</span><span class="headingEndMark"> — </span>Scoring systems for diagnosis of DIC in pregnant patients have been developed, but are neither widely used nor well-validated. </p><p class="bulletIndent1"><span class="glyph">●</span>One group adapted the International Society of Thrombosis and Hemostasis (ISTH) DIC scoring system for diagnosis of overt DIC for use in pregnant patients. The revised system includes platelet count, prothrombin time (PT) difference (difference between the PT value of the patient and laboratory control in seconds), and fibrinogen levels [<a href="#rid4">4</a>]. The parameters are assigned a score of 0, 1 (platelet count &lt;50,000 or 100,001 to 185,000 or fibrinogen 400 to 450 mg/dL), 2 (platelet count 50,000 to 100,000), 5 (for PT difference 0.5 to 1), 6 (for fibrinogen 300 to 400 mg/dL), 12 (for PT difference 1 to 1.5), or 25 (for PT difference &gt;1.5 or fibrinogen ≤300 mg/dL). In a study of 684 patients with abruption, of whom 150 needed blood transfusion and 43 had DIC, a score ≥26 had 88 percent sensitivity and 96 percent specificity to identify those who needed blood and blood product transfusion. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy-specific scoring systems for nonovert DIC have also been developed to predict patients likely to require blood product transfusion. The parameters include fibrinogen, antithrombin III, protein C, prothrombin time, platelet count, thrombin-antithrombin (TAT) complex, and D-dimer [<a href="#rid31">31</a>]. In one study, a score ≥3 had a sensitivity and specificity of 71.4 and 77.9 percent to identify patients at risk for obstetrical hemorrhage requiring blood product transfusion. </p><p></p><p class="headingAnchor" id="H194037429"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of DIC in pregnancy includes other causes of bleeding, thrombosis, and/or organ damage. In some cases, these conditions may coexist with DIC or contribute to the pathogenesis of DIC. Treatment of the underlying cause typically leads to resolution of DIC (see  <a class="medical medical_review" href="/d/html/130462.html" rel="external">"Disseminated intravascular coagulation (DIC) during pregnancy: Management and prognosis", section on 'Identify and address the triggering event'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum hemorrhage (PPH) with dilutional coagulopathy</strong> – Severe bleeding from PPH may result in dilutional coagulopathy. The reduced levels of coagulation factors can prolong the prothrombin time (PT) and activated partial thromboplastin time (aPTT) as in DIC. The blood smear is useful because there is no evidence of microangiopathy (no schistocytes) in PPH, while schistocytes should be evident in fulminant DIC. However, some patients with PPH may have elements of suggestive of coagulation factor consumption consistent with DIC. (See  <a class="medical medical_review" href="/d/html/6710.html" rel="external">"Overview of postpartum hemorrhage", section on 'Criteria for diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary thrombotic microangiopathy</strong> – Primary thrombotic microangiopathies such as thrombocytopenic purpura (TTP) are rare during pregnancy, but the physiologic stress of pregnancy may trigger clinical manifestations of hereditary or acquired TTP. Pregnancy (including the postpartum period) is also a major precipitating factor for complement-mediated hemolytic uremic syndrome. (See  <a class="medical medical_review" href="/d/html/114693.html" rel="external">"Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS", section on 'Pregnancy or postpartum'</a>.)</p><p></p><p class="bulletIndent1">Like DIC, patients with TTP may have Coombs-negative hemolytic anemia with schistocytes on the blood smear, thrombocytopenia, and organ damage. In contrast to DIC, the coagulation studies in TTP typically are normal, and the ADAMTS13 (A disintegrin and metalloproteinase with thrombospondin-like repeats-13) activity is severely reduced (eg, activity &lt;10 percent). Mild decreases in ADAMTS13 activity (eg, between 10 and 60 percent) are often seen in acutely ill pregnant patients (eg, preeclampsia, HELLP syndrome) and are not thought to be pathophysiologically or clinically significant [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/1338.html" rel="external">"Diagnosis of immune TTP"</a> and  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>von Willebrand disease (VWD)</strong> – VWD is the most common inherited bleeding disorder, and many pregnant patients with VWD are already aware of their diagnosis. Pregnancy is generally well-tolerated in most cases of VWD (in particular type 1, which may be asymptomatic or associated with mild bleeding symptoms), partly due to the physiologic increases in von Willebrand factor (VWF) levels. However, VWF levels decline in the postpartum period, and it is possible for a patient who has not had a prior hemostatic challenge to have marked postpartum bleeding as the initial manifestation of VWD [<a href="#rid33">33-35</a>].</p><p></p><p class="bulletIndent1">Like DIC, some types of severe VWD may be associated with thrombocytopenia and/or prolongation of the aPTT. Unlike DIC, VWD does not cause prolongation of the PT, a low fibrinogen level, or elevated D-dimer; and patients with VWD will have low levels of VWF, VWF activity (ristocetin cofactor activity), and factor VIII. (See  <a class="medical medical_review" href="/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid syndrome (APS)</strong> – APS is caused by autoantibodies to proteins bound to anionic phospholipid-protein complexes (the dominant protein target is beta2-glycoprotein I); it can occur in the setting of systemic lupus erythematosus or independently.</p><p></p><p class="bulletIndent1">Like DIC, patients can have thrombosis and elevated D-dimer, and the aPTT is frequently prolonged. Unlike DIC, in APS, the PT and fibrinogen levels are normal, and bleeding typically does not occur. Furthermore, the autoantibodies in APS can sometimes cause prolongation of the aPTT as a laboratory artifact (ie, lupus anticoagulant); they are actually prothrombotic. (See  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary embolism (PE)</strong> – PE is a leading cause of death in pregnant/postpartum persons and is often underappreciated due to the wide range of presenting symptoms.</p><p></p><p class="bulletIndent1">Like DIC, patients with PE may present with shock and elevated D-dimer. Unlike DIC, PE generally is not associated with bleeding, prolongation of the clotting times, or low fibrinogen. (See  <a class="medical medical_review" href="/d/html/89374.html" rel="external">"Pulmonary embolism in pregnancy: Clinical presentation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparin-induced thrombocytopenia (HIT)</strong> – HIT is a potentially life-threatening disorder in which autoantibodies cause activation of platelets in the presence of heparin (ie, the antibodies are prothrombotic). HIT is extremely rare in pregnancy.</p><p></p><p class="bulletIndent1">Like DIC, HIT can present with thrombocytopenia, thrombosis, and/or organ damage; bleeding may be present due to the heparin. Unlike DIC, HIT has a temporal relationship to heparin exposure; patients with HIT have positive testing for HIT antibodies and do not have coagulation abnormalities (except for those due to their anticoagulant). (See  <a class="medical medical_review" href="/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion reaction</strong> – Severe transfusion reactions, especially due to ABO incompatibility, can mimic or cause DIC.</p><p></p><p class="bulletIndent1">Like DIC, a severe transfusion reaction from ABO mismatch can cause anemia, thrombocytopenia, oozing from mucocutaneous sites, and bleeding. Unlike DIC, transfusion reactions have a history of antecedent transfusion and often are associated with a positive direct antiglobulin (Coombs) test. (See  <a class="medical medical_review" href="/d/html/95132.html" rel="external">"Approach to the patient with a suspected acute transfusion reaction", section on 'Acute hemolytic transfusion reaction (AHTR)'</a>.)</p><p></p><p>Additional discussion of the differential diagnosis in nonobstetric patients is reviewed separately. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H4198637239"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118733.html" rel="external">"Society guideline links: Obstetric hemorrhage"</a>.)</p><p class="headingAnchor" id="H2069681000"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/17113.html" rel="external">"Patient education: Disseminated intravascular coagulation (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1517580514"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Disseminated intravascular coagulation (DIC) is a secondary manifestation of an underlying primary cause of uncontrolled activation of coagulation and fibrinolysis. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Underlying cause</strong> – DIC typically occurs in the setting of one of the following pregnancy complications:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Placental abruption</p><p class="bulletIndent2"><span class="glyph">•</span>Preeclampsia with severe features/eclampsia/HELLP syndrome (hemolysis, elevated liver enzymes, low platelets)</p><p class="bulletIndent2"><span class="glyph">•</span>Amniotic fluid embolism</p><p class="bulletIndent2"><span class="glyph">•</span>Acute fatty liver of pregnancy</p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy-related sepsis (eg, septic abortion, severe chorioamnionitis, or severe postpartum endometritis) </p><p></p><p class="bulletIndent1">Postpartum hemorrhage (PPH) by itself usually does not cause consumptive coagulopathy unless associated with increased release of tissue factor but can lead to a dilutional coagulopathy. Prolonged retention of a dead fetus over several weeks is now a rare cause of DIC because these cases are identified early and delivered without significant delay. (See <a class="local">'Causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – The prevalence of DIC in pregnancy ranges from 0.03 to 0.35 percent in population-based studies or 12.5 per 10,000 delivery hospitalizations (0.13 percent). Although the overall prevalence of DIC is low in pregnancy, the frequency of DIC in patients with specific pregnancy complications, such as amniotic fluid embolism or placental abruption, can be very high. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of acute DIC in a pregnant patient is made when the clinical setting is appropriate and there is laboratory evidence of consumptive coagulopathy characterized by thrombocytopenia, coagulation factor consumption (eg, prolonged prothrombin time [or international normalized ratio] and activated partial thromboplastin time; low fibrinogen), and fibrinolysis (eg, increasing D-dimer, thromboelastography evidence of accelerated fibrinolysis). Bleeding is often present but is not required for diagnosis. (See <a class="local">'Clinical findings'</a> above and <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of DIC in pregnancy includes other causes of bleeding, thrombosis, and/or organ damage, which may coexist with DIC or contribute to its pathogenesis. These include PPH with dilutional coagulopathy, primary thrombotic microangiopathy, von Willebrand disease, antiphospholipid syndrome, pulmonary embolism, heparin-induced thrombocytopenia, and transfusion reaction. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3898612060"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kirk D Ramin, MD, and Susan Ramin, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Levi M. Disseminated intravascular coagulation (DIC) in pregnancy and the peri-partum period. Thromb Res 2009; 123 Suppl 2:S63.</a></li><li><a class="nounderline abstract_t">Callaghan WM, Creanga AA, Kuklina EV. Severe maternal morbidity among delivery and postpartum hospitalizations in the United States. Obstet Gynecol 2012; 120:1029.</a></li><li><a class="nounderline abstract_t">Rattray DD, O'Connell CM, Baskett TF. Acute disseminated intravascular coagulation in obstetrics: a tertiary centre population review (1980 to 2009). J Obstet Gynaecol Can 2012; 34:341.</a></li><li><a class="nounderline abstract_t">Erez O, Novack L, Beer-Weisel R, et al. DIC score in pregnant women--a population based modification of the International Society on Thrombosis and Hemostasis score. PLoS One 2014; 9:e93240.</a></li><li><a class="nounderline abstract_t">Shamshirsaz AA, Clark SL. Amniotic Fluid Embolism. Obstet Gynecol Clin North Am 2016; 43:779.</a></li><li><a class="nounderline abstract_t">Gilbert WM, Danielsen B. Amniotic fluid embolism: decreased mortality in a population-based study. Obstet Gynecol 1999; 93:973.</a></li><li><a class="nounderline abstract_t">Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993; 169:1000.</a></li><li><a class="nounderline abstract_t">Sher G. Pathogenesis and management of uterine inertia complicating abruptio placentae with consumption coagulopathy. Am J Obstet Gynecol 1977; 129:164.</a></li><li><a class="nounderline abstract_t">Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev 2009; 23:167.</a></li><li><a class="nounderline abstract_t">Erez O, Mastrolia SA, Thachil J. Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. Am J Obstet Gynecol 2015; 213:452.</a></li><li><a class="nounderline abstract_t">Lockwood CJ, Murk W, Kayisli UA, et al. Progestin and thrombin regulate tissue factor expression in human term decidual cells. J Clin Endocrinol Metab 2009; 94:2164.</a></li><li><a class="nounderline abstract_t">Lockwood CJ, Paidas M, Murk WK, et al. Involvement of human decidual cell-expressed tissue factor in uterine hemostasis and abruption. Thromb Res 2009; 124:516.</a></li><li><a class="nounderline abstract_t">Papageorgiou C, Jourdi G, Adjambri E, et al. Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. Clin Appl Thromb Hemost 2018; 24:8S.</a></li><li><a class="nounderline abstract_t">Hossain N, Paidas MJ. Disseminated intravascular coagulation. Semin Perinatol 2013; 37:257.</a></li><li><a class="nounderline abstract_t">Van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am 1998; 12:1141.</a></li><li><a class="nounderline abstract_t">Romero R, Mazor M, Lockwood CJ, et al. Clinical significance, prevalence, and natural history of thrombocytopenia in pregnancy-induced hypertension. Am J Perinatol 1989; 6:32.</a></li><li><a class="nounderline abstract_t">Cunningham FG, Nelson DB. Disseminated Intravascular Coagulation Syndromes in Obstetrics. Obstet Gynecol 2015; 126:999.</a></li><li><a class="nounderline abstract_t">Takai H, Kondoh E, Sato Y, et al. Disseminated intravascular coagulation as the presenting sign of gastric cancer during pregnancy. J Obstet Gynaecol Res 2011; 37:1717.</a></li><li><a class="nounderline abstract_t">Morimatsu Y, Matsubara S, Hirose N, et al. Acute promyelocytic leukemia: an unusual cause showing prolonged disseminated intravascular coagulation after placental abruption. Arch Gynecol Obstet 2008; 277:267.</a></li><li><a class="nounderline abstract_t">Levi M, Meijers JC. DIC: which laboratory tests are most useful. Blood Rev 2011; 25:33.</a></li><li><a class="nounderline abstract_t">Collis RE, Collins PW. Haemostatic management of obstetric haemorrhage. Anaesthesia 2015; 70 Suppl 1:78.</a></li><li><a class="nounderline abstract_t">Collins PW, Lilley G, Bruynseels D, et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood 2014; 124:1727.</a></li><li><a class="nounderline abstract_t">Liu J, Yuan E, Lee L. Gestational age-specific reference intervals for routine haemostatic assays during normal pregnancy. Clin Chim Acta 2012; 413:258.</a></li><li><a class="nounderline abstract_t">Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol 2009; 114:1326.</a></li><li><a class="nounderline abstract_t">Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999; 82:695.</a></li><li><a class="nounderline abstract_t">Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5:266.</a></li><li><a class="nounderline abstract_t">Murphy N, Broadhurst DI, Khashan AS, et al. Gestation-specific D-dimer reference ranges: a cross-sectional study. BJOG 2015; 122:395.</a></li><li><a class="nounderline abstract_t">Kovac M, Mikovic Z, Rakicevic L, et al. The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy. Eur J Obstet Gynecol Reprod Biol 2010; 148:27.</a></li><li><a class="nounderline abstract_t">Johansson PI, Stensballe J, Ostrowski SR. Current management of massive hemorrhage in trauma. Scand J Trauma Resusc Emerg Med 2012; 20:47.</a></li><li><a class="nounderline abstract_t">Sussman LN. The clotting time--an enigma. Am J Clin Pathol 1973; 60:651.</a></li><li><a class="nounderline abstract_t">Alhousseini A, Romero R, Benshalom-Tirosh N, et al. Nonovert disseminated intravascular coagulation (DIC) in pregnancy: a new scoring system for the identification of patients at risk for obstetrical hemorrhage requiring blood product transfusion. J Matern Fetal Neonatal Med 2022; 35:242.</a></li><li><a class="nounderline abstract_t">Stepanian A, Cohen-Moatti M, Sanglier T, et al. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. Arterioscler Thromb Vasc Biol 2011; 31:1703.</a></li><li><a class="nounderline abstract_t">Huq FY, Kulkarni A, Agbim EC, et al. Changes in the levels of factor VIII and von Willebrand factor in the puerperium. Haemophilia 2012; 18:241.</a></li><li><a class="nounderline abstract_t">Sánchez-Luceros A, Meschengieser SS, Marchese C, et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003; 14:647.</a></li><li><a class="nounderline abstract_t">Noller KL, Bowie EJ, Kempers RD, Owen CA Jr. Von Willebrand's disease in pregnancy. Obstet Gynecol 1973; 41:865.</a></li></ol></div><div id="topicVersionRevision">Topic 4460 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217479" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Disseminated intravascular coagulation (DIC) in pregnancy and the peri-partum period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090519" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Severe maternal morbidity among delivery and postpartum hospitalizations in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22472333" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Acute disseminated intravascular coagulation in obstetrics: a tertiary centre population review (1980 to 2009).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24728139" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : DIC score in pregnant women--a population based modification of the International Society on Thrombosis and Hemostasis score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816160" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Amniotic Fluid Embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362165" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Amniotic fluid embolism: decreased mortality in a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8238109" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/302645" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pathogenesis and management of uterine inertia complicating abruptio placentae with consumption coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19442424" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Disseminated intravascular coagulation in obstetric disorders and its acute haematological management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25840271" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19276228" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Progestin and thrombin regulate tissue factor expression in human term decidual cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19720393" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Involvement of human decidual cell-expressed tissue factor in uterine hemostasis and abruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30296833" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23916024" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Disseminated intravascular coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922930" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Laboratory evaluation of hypercoagulable states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2783368" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical significance, prevalence, and natural history of thrombocytopenia in pregnancy-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26444122" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Disseminated Intravascular Coagulation Syndromes in Obstetrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21676072" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Disseminated intravascular coagulation as the presenting sign of gastric cancer during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17713776" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acute promyelocytic leukemia: an unusual cause showing prolonged disseminated intravascular coagulation after placental abruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20950905" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : DIC: which laboratory tests are most useful.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25440400" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Haemostatic management of obstetric haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25024304" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22001049" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gestational age-specific reference intervals for routine haemostatic assays during normal pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935037" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pregnancy and laboratory studies: a reference table for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10605770" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Disseminated intravascular coagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17087729" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24828148" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gestation-specific D-dimer reference ranges: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19804940" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22776724" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Current management of massive hemorrhage in trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4584561" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The clotting time--an enigma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31931643" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nonovert disseminated intravascular coagulation (DIC) in pregnancy: a new scoring system for the identification of patients at risk for obstetrical hemorrhage requiring blood product transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21512165" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21951573" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Changes in the levels of factor VIII and von Willebrand factor in the puerperium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14517489" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4541087" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Von Willebrand's disease in pregnancy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
